The consensus story is cleaner than it looks. Seven analysts, seven buy ratings, Q1 results that beat on both revenue and EBITDA. The SSS deceleration — +0.5% vs. +5.5% the prior quarter — is the one number bears will reach for, but every analyst attributes it to January weather and an industry-wide consumption slowdown. HITI actually gained market share in that environment, hitting 12% across its five provinces. That’s not a struggling company; that’s a consolidator doing its job while weaker operators bleed.

Where they diverge: Remexian’s trajectory. Price targets span C$5.00 to C$8.00 — a 60% range — and that gap is almost entirely explained by different assumptions about how fast Remexian scales. Beacon models a C$14M EBITDA contribution from Germany by year-end (run-rate); the more conservative estimates assume the Portugal biomass delay persists longer. February’s C$12M at 20% gross margin was a strong data point for the bulls. Q2 results will be the first real test of whether that margin is a trend or a one-month blip. If the Portugal inventory releases cleanly and margin holds in the 18-22% band, the C$7-8 targets start to look reasonable. If it slips, C$5-6.50 becomes the credible anchor.

The most interesting report isn’t a Q1 earnings note. ATB’s March 11 CBD thematic is the sleeper in this batch. The US CBD operations — NuLeaf Naturals, FAB CBD — are currently a drag on HITI’s consolidated numbers and are effectively valued at zero or negative by the market. The CMS Medicare CBD pilot ($500/yr for beneficiaries, $400M–$1.7B potential market) is a binary catalyst that nobody is pricing in. HITI positioned itself as a founding member of the NCCC on March 4 — two weeks before anyone published a Q1 earnings note. That’s intentional. If the pilot lands, the narrative on the US segment flips from “drag” to “growth option.” The risk is real (November hemp ban could kill full-spectrum), but the asymmetry is significant.

The three-segment lens is the right frame. Canada is the engine: profitable, best-in-class unit economics, gaining share, and still underpenetrated in Ontario and Alberta. Germany is the growth bet: 10.3% market share and rising, Remexian acquisition looking increasingly shrewd at the C$43.7M / 51% entry price, UK expansion next. US CBD is the free option: currently burning cash but a single regulatory catalyst away from becoming a meaningful contributor. The market at C$3.36 is pricing in Canada with no credit for Germany’s trajectory or US optionality. That’s the gap analysts are exploiting.

What to watch in Q2 (June results): Remexian margin is the single most important variable. If EBITDA margin exits Q2 above 10%, the bull thesis is intact. Store count trajectory (20-30 guided for FY26, 7 already opened in Q1) and any UK M&A announcement are secondary but meaningful catalysts. The credibility gap — C$3.36 vs. C$5-8 analyst consensus — closes through execution, not narrative. H2/26 is when this plays out.